Literature DB >> 18785931

From yeast killer toxins to antibiobodies and beyond.

Walter Magliani1, Stefania Conti, Luiz R Travassos, Luciano Polonelli.   

Abstract

Antibiobodies are paradigmatic of yeast killer toxin (KT)-like antibodies (KAbs) mimicking the antimicrobial activity of KTs in the frame of the yeast killer phenomenon. Polyclonal, monoclonal and recombinant anti-idiotypic antibiobodies (anti-idiotypic KAbs), internal images of a wide-spectrum KT produced by the yeast Pichia anomala (PaKT), have been produced by immunization with the idiotype of a PaKT-neutralizing monoclonal antibody. Anti-idiotypic KAbs showed microbicidal activity against eukaryotic and prokaryotic pathogenic agents through the interaction with specific KT receptors (KTRs), putatively constituted by beta-glucans. Natural KAbs have been found in animals and humans experimentally or naturally infected by KTR-bearing microorganisms. Recombinant KAb-derived synthetic killer peptides showed further antiviral and immunomodulatory activities. The perspectives of KAbs and killer peptides as potential sources of novel therapeutic agents, and of KTRs and idiotypes as vaccines against infectious diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785931     DOI: 10.1111/j.1574-6968.2008.01340.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  9 in total

1.  Production of a novel and cold-active killer toxin by Mrakia frigida 2E00797 isolated from sea sediment in Antarctica.

Authors:  Ming-Xia Hua; Zhe Chi; Guang-Lei Liu; Muhammad Aslam Buzdar; Zhen-Ming Chi
Journal:  Extremophiles       Date:  2010-10-26       Impact factor: 2.395

Review 2.  Mycoviruses: future therapeutic agents of invasive fungal infections in humans?

Authors:  W W J van de Sande; J R Lo-Ten-Foe; A van Belkum; M G Netea; B J Kullberg; A G Vonk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-02       Impact factor: 3.267

3.  Disruption of the gene encoding β-1, 3-glucanase in marine-derived Williopsis saturnus WC91-2 enhances its killer toxin activity.

Authors:  Jin-Li Xu; Xue Zhang; Huai-Yong Sun; Zhen-Ming Chi
Journal:  Mar Biotechnol (NY)       Date:  2011-10-08       Impact factor: 3.619

4.  Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.

Authors:  Andrey S Dobroff; Elaine G Rodrigues; Maria A Juliano; Dayson M Friaça; Ernesto S Nakayasu; Igor C Almeida; Renato A Mortara; Jacqueline F Jacysyn; Gustavo P Amarante-Mendes; Walter Magliani; Stefania Conti; Luciano Polonelli; Luiz R Travassos
Journal:  Transl Oncol       Date:  2010-08-01       Impact factor: 4.243

5.  Identification and characterization of yeasts isolated from sedimentary rocks of Union Glacier at the Antarctica.

Authors:  Salvador Barahona; Yassef Yuivar; Gabriel Socias; Jennifer Alcaíno; Víctor Cifuentes; Marcelo Baeza
Journal:  Extremophiles       Date:  2016-05-23       Impact factor: 2.395

6.  Antibody Peptide based antifungal immunotherapy.

Authors:  Walter Magliani; Stefania Conti; Laura Giovati; Pier Paolo Zanello; Martina Sperindè; Tecla Ciociola; Luciano Polonelli
Journal:  Front Microbiol       Date:  2012-06-01       Impact factor: 5.640

7.  In Vitro and In Vivo Anti-Candida Activity and Structural Analysis of Killer Peptide (KP)-Derivatives.

Authors:  Tecla Ciociola; Thelma A Pertinhez; Tiziano De Simone; Walter Magliani; Elena Ferrari; Silvana Belletti; Tiziana D'Adda; Stefania Conti; Laura Giovati
Journal:  J Fungi (Basel)       Date:  2021-02-10

8.  Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications.

Authors:  Rima Hatoum; Steve Labrie; Ismail Fliss
Journal:  Front Microbiol       Date:  2012-12-19       Impact factor: 5.640

Review 9.  Wickerhamomyces Yeast Killer Toxins' Medical Applications.

Authors:  Laura Giovati; Tecla Ciociola; Tiziano De Simone; Stefania Conti; Walter Magliani
Journal:  Toxins (Basel)       Date:  2021-09-15       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.